Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ischemia Technologies Inc.

Latest From Ischemia Technologies Inc.

Inverness Buys Bulk

Inverness Medical Innovations, a point-of-care diagnostics company, made a splash with its $1.6 billion acquisition of Biosite. But the purchase was merely the latest step in a long-time strategy of growing through acquisition.

Medical Device

ITI Life Sciences: Scotland Minds the Funding Gap

Scotlands ITI Life Sciences aims to create a unique model for plugging the widening funding gap between publicly funded research and venture-funded commercialization of technology. The firm's first four programs reflect the various ways it aims to drum up life sciences business in Scotland.

Europe Business Strategies

Can Ischemia Technologies Produce the Next Big Cardiac Marker?

In recent years, some creative diagnostic companies have applied pharmaceutical-like marketing techniques to launches of their flagship products. Five-year-old Ischemia Technologies' launch strategy for its cardiac marker, ischemia-modified albumin (IMA) is based on tenets gleaned from these companies' success stories. It is supporting its marker of cardiac ischemia with strong clinical and market development programs, aimed not just at the laboratory but also at clinicians. But the inherent complexities and nuances of the opportunity it addresses are challenging.

Medical Device Clinical Trials

Cardiac Diagnostics: The Horse is Out of the Barn

The cardiac diagnostic marker field, dormant for years, is changing so rapiidly that studies done five years ago are out of date. Current markers are inreasingly significant in guiding treatment and a lot of promising new markers are in development. As new markers attract the interest of researchers and clinicians, their adoption is likely to be influenced by the history of troponins for detecting MI and the up-and-coming marker for heart failure, BNP. That's the message of E. Magnus Ohman, MD, chief of the division of cardiology at UNC, who spoke at the AACC's annual meeting in July.

Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay